Subscribe to Search results

The Caxton Foundation's annual census of beneficiaries was cancelled until a regular payment system was introduced.

Published on:

There were lengthy delays in processing early applications at the Caxton Foundation.

Published on:

The annual report to the Charity Commissioners was not sent to beneficiaries.

Published on:

Extracts were taken from census forms to inform the National Welfare Committee's consideration of grant applications.

Published on:

Caxton Foundation staff had reference guidelines on what items beneficiaries could receive grants for.

Published on:

The Caxton Foundation was proactive in helping beneficiaries manage their debts.

Published on:

The National Welfare Committee and Caxton Foundation staff aimed to be consistent by checking what had been awarded previously in similar circumstances.

Published on:

Some applicants who admitted to intranasal or oral drug consumption, but not to injection, were denied on the basis of intravenous drug use, even though their medical records contained no reference to any such use.

Published on:

Professor Howard Thomas gave evidence to the Inquiry that previous studies and evidence regarding concerns about non-A non-B Hepatitis in the late 1970s and early 1980s were 'all in accord'.

Published on:

In his oral evidence, Professor Howard Thomas agreed that he had given the Glasgow Symposium the message that there would be problems in the future with hepatitis, fibrosis and cirrhosis.

Published on:

Mark Mildred was told by Nicholas Fish when he began working for the Skipton Panel and asked what sort of decision was wanted, to provide "A letter, keeping it as brief and simple as you can."

Published on:

Mark Mildred was not initially given, nor did he ask for, a copy of the Agency Agreement under which the Skipton Fund operated under the Department of Health.

Published on:

Unsuccessful applicants to the Skipton Fund were ignorant of the detail of reasoning that led to the rejection of their claims. Nicholas Fish noted that those who had asked for a copy of letters and reports relating to their decision would have been given one.

Published on:

After Ann Lloyd became chair of the Caxton Foundation more effort was made to let more potential applicants know of the Foundation.

Published on:

At the outset of her appointment as CEO of the Haemophilia Society, Karin Pappenheim was given to understand that the campaign for compensation for people with haemophilia infected with Hepatitis C was a very high priority.

Published on:

The Society, to save costs, chose to use a single low-cost freelancer for selected public affairs and campaign functions.

Published on:

From the Society's perspective the announcement of the setup of the Skipton Fund came out of the blue.

Published on:

The Society did not specifically campaign for a scheme which would provide financial support for certain groups, such as the bereaved or those caring for family members or partners who were infected.

Published on:

William Wright told the Inquiry that people felt that although they were writing to MPs, their voices were not being heard.

Published on:

Lynne Kelly, chair of Haemophilia Wales, told the Inquiry that the Welsh Government had been briefed by Westminster so hadn't felt there was any need for a public inquiry.

Published on: